title: MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT).
abstract: MiR-30a can target multiple proteins involved in epithelial-to-mesenchymal transition (EMT). In this study, we investigated the association between miR-30a and cisplatin (DDP) sensitivity in gastric cancer. In addition, the regulation of miR-30a in EMT in SGC-7901 cells and SGC-7901/DDP cells and their involvement in cisplatin sensitivity were further investigated.
  
  
  
  20 advanced gastric cancer patients who received platinum-based chemotherapy were recruited. Chemosensitivity was assessed after completion of the therapy. MiR-30a expression was quantified and compared between chemosensitive and chemoresistant groups. SGC-7901 cells and SGC-7901/DDP cells were further used for the in-vitro gain-and-loss study to investigate the effect of miR-30a on EMT and cisplatin sensitivity.
  
  
  
  Chemosensitive patients had significantly higher miR-30a expression than the chemoresistant counterparts. SGC-7901 cells had significantly higher miR-30a expression than SGC-7901/DDP cells. Knockdown of endogenous miR-30a promoted the elongated fibroblast-like morphologic alteration of SGC-7901 cells and also enhanced Snail and Vimentin expression. MiR-30a overexpression induced morphological changes from an extended, fibroblast-like morphology to more epithelial-like morphology in SGC-7901/DDP cells and decreased Snail and Vimentin level. The cancer cells with miR-30a overexpression had significantly higher DDP sensitivity, while the cells with miR-30a knockdown had decreased sensitivity.
  
  
  
  EMT is associated with cisplatin resistance in gastric cancer. MiR-30a is an important miRNA modulating EMT and cisplatin sensitivity of SGC-7901 and SGC-7901/DDP cells.
authors.affiliation: Clinical Laboratory, the Central Hospital of Yishui, Linyi, Shandong, China. jiankunchu@outlook.com.
authors.forename: L-L
authors.initials: LL
authors.lastname: Wang
authors.forename: X-H
authors.initials: XH
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: J-K
authors.initials: JK
authors.lastname: Chu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use*; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C546086:MIRN30b microRNA, human; D035683:MicroRNAs; D002945:Cisplatin